|
|
|
|
|
L’historique des informations financières est fourni par Reuters. Axcan Pharma Inc. ne fait aucune représentation ni garantie par rapport à ces informations et n’accepte aucunement la responsabilité pour les informations supplémentaires, les amendements ou les mises à jour.
Disponible en anglais seulement
Quarterly Income Statement
View Annual Income Statement
In Millions of U.S. Dollars
(except for per share items)
|
Quarter Ending
31 Dec 07
|
Quarter Ending
31 Dec 07
|
Quarter Ending
30 Sep 07
|
| |
Revenue |
92.9 |
92.9 |
92.5 |
| |
Other Revenue, Total |
– |
– |
– |
| |
Total Revenue |
92.9 |
92.9 |
92.5 |
| |
Cost of Revenue |
22.4 |
22.4 |
22.6 |
| |
Gross Profit |
70.5 |
70.5 |
69.9 |
| |
Selling/General/Admin. Expenses, Total |
32.6 |
32.6 |
27.7 |
| |
Research & Development |
5.5 |
5.5 |
7.2 |
| |
Depreciation/Amortization |
5.9 |
5.9 |
5.8 |
| |
Interest Expense/Income, Net |
( 3.5) |
( 3.5) |
( 2.4) |
| |
Unusual Expense (Income) |
– |
– |
10.0 |
| |
Other Operating Expense, Total |
– |
– |
– |
|
Total Operating Expense |
63.0 |
63.0 |
71.0 |
| |
Operating Income |
29.9 |
29.9 |
21.5 |
| |
Interest Income (Expense), Net Non-Op |
– |
– |
– |
| |
Gain (Loss) on Sale of Assets |
– |
– |
– |
| |
Other, Net |
– |
– |
– |
| |
Income Before Tax |
29.9 |
29.9 |
21.5 |
| |
Income Tax - Total |
7.6 |
7.6 |
4.7 |
| |
Income After Tax |
22.3 |
22.3 |
16.8 |
| |
Minority Interest |
– |
– |
– |
| |
Equity In Affiliates |
– |
– |
– |
| |
Net Income Before Extra. Item |
22.3 |
22.3 |
16.8 |
| |
Accounting Change |
– |
– |
– |
| |
Discontinued Operations |
– |
– |
– |
| |
Extraordinary Item |
– |
– |
– |
| |
Net Income |
22.3 |
22.3 |
16.8 |
| |
Preferred Dividends |
– |
– |
– |
| |
Income Avail To Common Excl. Extra. Items |
22.3 |
22.3 |
16.8 |
| |
Income Avail To Common Incl. Extra. Items |
22.3 |
22.3 |
16.8 |
| |
Basic/Primary Weighted Average Shares |
56.0 |
56.0 |
55.3 |
| |
Basic/Primary EPS Excl. Extra. Items |
0.4 |
0.4 |
0.3 |
| |
Basic/Primary EPS Incl. Extra. Items |
0.4 |
0.4 |
0.3 |
| |
Dilution Adjustment |
– |
– |
– |
| |
Diluted Weighted Average Shares |
56.8 |
56.8 |
56.1 |
| |
Diluted EPS Excl. Extra. Items |
0.4 |
0.4 |
0.3 |
| |
Diluted EPS Incl. Extra. Items |
0.4 |
0.4 |
0.3 |
| |
DPS-Common Stock |
– |
– |
– |
| |
Gross Dividends Common |
– |
– |
– |
| |
Interest Expense |
0.2 |
0.2 |
0.1 |
| |
Depreciation |
5.9 |
5.9 |
1.5 |
| |
Total Special Items |
– |
– |
10.0 |
| |
Normalized Pre-Tax Income |
29.9 |
29.9 |
31.5 |
| |
Effect of Sp. Charge on Inc. Taxes |
– |
– |
– |
| |
Income Taxes Ex. Impact of Special Items |
7.6 |
7.6 |
4.7 |
| |
Normalized Income After Taxes |
22.3 |
22.3 |
26.8 |
| |
Normalized Income Available to Common |
22.3 |
22.3 |
26.8 |
| |
Basic Normalized EPS |
0.4 |
0.4 |
0.5 |
| |
Diluted Normalized EPS |
0.4 |
0.4 |
0.5 |
|
|
|
|
|
|
|
| |
|
|
|
